Cognition Therapeutics, Inc. (CGTX)

- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer's Disease -

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi will participate in an “unplugged” fireside discussion at the annual Piper Sandler Healthcare Conference. The conference will take place December 2-4, 2025 at The Lotte New York Palace hotel.

Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium

- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.

Cognition Therapeutics (NASDAQ: CGTX - Get Free Report) and XOMA Royalty (NASDAQ: XOMA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends. Earnings and Valuation This table compares Cognition

Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START' Study has reached the 75% enrollment mark. The START Study is enrolling approximately 540 individuals with mild cognitive impairment (MCI) and early Alzheimer's disease who will be treated with zervimesine (CT1812) or placebo for 18 months. Cognition is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) with funding from the National Institute of Aging (NIA) at the National Institutes of Health.

PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately $30 million, before deducting placement agent fees and other offering expenses.

- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that it has entered into a securities purchase agreement for the purchase and sale of 14,700,000 shares of its common stock pursuant to a registered direct offering.

I rate Cognition Therapeutics a "Strong Buy" due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low p-tau217; Successful results means NDA filing. Zervimesine showed a remarkable 95% slowing of cognitive decline in the low-ptau217 biomarker-defined subgroup, supporting a precision medicine approach and strong phase 3 prospects. The company is well-financed through government grants and has multiple funding options, with operational funding into Q2 2026, reducing near-term dilution risk.

- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, received final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the end-of-Phase 2 meeting that was conducted on July 9, 2025.

Cognition Therapeutics (CGTX -4.78%), a clinical-stage biotechnology firm focused on developing therapies for neurodegenerative diseases, released its earnings for Q2 2025 on August 7, 2025. The company reported a GAAP net loss per share of $(0.11) for Q2 2025, missing consensus estimates by $(0.005)

- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment - - Plasma and CSF biomarkers support zervimesine's impact on Alzheimer's disease biology -

In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL Study